 |
31 Diseases |  |
34 Trials |
|
34 Trials |  |
1690 News |  |
| «12...78910111213141516171819» |
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment open, Monotherapy: Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Mar 23, 2014
P4, N=30, Recruiting, Sponsor: Postgraduate Institute of Medical Education and Research
Not yet recruiting --> Recruiting
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Byetta (exenatide) / AstraZeneca
New P4 trial: SAFEGUARD: Safety Evaluation of Adverse Reactions in Diabetes (clinicaltrials.gov) - Mar 18, 2014
P4, N=60, Not yet recruiting, Sponsor: Charles University, Czech Republic
- |||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment open: IMPERIUM: A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) (clinicaltrials.gov) - Mar 9, 2014
P4, N=880, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P3 trial: Lina-Plaque: Effect of Linagliptin on Vascular Inflammation in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Mar 2, 2014
P3, N=60, Not yet recruiting, Sponsor: RWTH Aachen University
- ||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P4 trial: IMPERIUM: A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) (clinicaltrials.gov) - Feb 24, 2014
P4, N=880, Recruiting, Sponsor: Eli Lilly and Company
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P4 trial: ADA Linagliptin in Long Term Care (clinicaltrials.gov) - Feb 11, 2014
P4, N=150, Not yet recruiting, Sponsor: Emory University
- Juvisync (sitagliptin/simvastatin) / Merck (MSD), Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion: Glucagon-like Peptide (GLP) Utilization and Safety (clinicaltrials.gov) - Feb 5, 2014
P=N/A, N=1, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Trial completion: Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto (clinicaltrials.gov) - Feb 4, 2014
P1, N=36, Completed, Sponsor: Boehringer Ingelheim Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion: Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation) (clinicaltrials.gov) - Jan 21, 2014
P1, N=42, Completed, Sponsor: Boehringer Ingelheim Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment change: Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Jan 20, 2014
P=N/A, N=918, Terminated, Sponsor: Boehringer Ingelheim Pharmaceuticals
Active, not recruiting --> Completed N=174 --> 918
- Bariatric surgery: Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment (clinicaltrials.gov) - Jan 20, 2014
P4, N=20, Not yet recruiting, Sponsor: Khoo Teck Puat Hospital
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P3 trial, Monotherapy: Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early Diabetes (clinicaltrials.gov) - Dec 17, 2013
P3, N=40, Recruiting, Sponsor: dr. DJ Mulder
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P4 trial, Surgery: Linagliptin Inpatient Trial (clinicaltrials.gov) - Dec 5, 2013
P4, N=280, Not yet recruiting, Sponsor: Emory University
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment open: Diastolic Dysfunction in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Oct 27, 2013
P3, N=60, Recruiting, Sponsor: RWTH Aachen University
N=174 --> 918 Not yet recruiting --> Recruiting
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment open, Surgery: PRODIGIES: Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines (clinicaltrials.gov) - Oct 26, 2013
P=N/A, N=150, Recruiting, Sponsor: Pontificia Universidad Catolica de Chile
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P4 trial: The Effect of Linagliptin on Mitochondrial and Endothelial Function (clinicaltrials.gov) - Oct 23, 2013
P4, N=40, Recruiting, Sponsor: Beth Israel Deaconess Medical Center
- ||||| Gemiglo (gemigliptin) / Sanofi, LG Chem
New P4 trial: A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study) (clinicaltrials.gov) - Oct 21, 2013
P4, N=148, Recruiting, Sponsor: LG Life Sciences
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment open: The Effect of Linagliptin on Mitochondrial and Endothelial Function (clinicaltrials.gov) - Oct 20, 2013
P4, N=40, Recruiting, Sponsor: Beth Israel Deaconess Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
New P1 trial: Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto (clinicaltrials.gov) - Sep 18, 2013
P1, N=36, Completed, Sponsor: Boehringer Ingelheim Pharmaceuticals
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P1 trial: Linagliptin in Schizophrenia Patients (clinicaltrials.gov) - Sep 12, 2013
P1, N=5, Recruiting, Sponsor: Monash University
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment open: Linagliptin in Schizophrenia Patients (clinicaltrials.gov) - Sep 10, 2013
P1, N=5, Recruiting, Sponsor: Monash University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Clinical: PMS of Trazenta on the Long-term Use as Add-on Therapy (clinicaltrials.gov) - Jul 18, 2013
P=N/A, N=3000, Recruiting, Sponsor: Boehringer Ingelheim
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Clinical: A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea (clinicaltrials.gov) - Jul 17, 2013
P=N/A, N=600, Recruiting, Sponsor: Boehringer Ingelheim
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P4 trial: Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment (clinicaltrials.gov) - Jul 17, 2013
P4, N=30, Recruiting, Sponsor: Profil Institut f
- |||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment open: Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA) (clinicaltrials.gov) - Jul 11, 2013
P4, N=8300, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P4 trial: Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA) (clinicaltrials.gov) - Jul 10, 2013
P4, N=8300, Recruiting, Sponsor: Boehringer Ingelheim
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P3 trial: Diastolic Dysfunction in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Jun 26, 2013
P3, N=60, Recruiting, Sponsor: RWTH Aachen University
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment change: Long-term Daily Use of Trazenta (clinicaltrials.gov) - May 1, 2013
P=N/A, N=3300, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting N=6600 --> 3300
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P4 trial: The impact on the blood sugar lowering drug Linagliptin and blood vessel function in patients with type 2 diabetes Der Einfluss der blutzuckersenkenden Substanz Linagliptin auf die Blutgef (EUDRACT) - Apr 22, 2013
P4, N=50, Ongoing, Sponsor: Medizinische Universit
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P3 trial: Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes. (clinicaltrials.gov) - Apr 17, 2013
P3, N=65, Completed, Sponsor: University of Erlangen-N
- |||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Trial completion, Monotherapy, Head-to-Head: Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes (clinicaltrials.gov) - Apr 16, 2013
P4, N=316, Completed, Sponsor: Boehringer Ingelheim Pharmaceuticals
N=6600 --> 3300 Active, not recruiting --> Completed
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Clinical: Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Apr 4, 2013
P=N/A, N=918, Terminated, Sponsor: Boehringer Ingelheim Pharmaceuticals
- ||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment closed: CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes (clinicaltrials.gov) - Mar 5, 2013
P3, N=6000, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion, Combination therapy: Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control (clinicaltrials.gov) - Mar 5, 2013
P4, N=689, Completed, Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion, Combination therapy, Monotherapy: 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks (clinicaltrials.gov) - Mar 5, 2013
P3, N=936, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P3 trial: MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin (clinicaltrials.gov) - Feb 13, 2013
P3, N=404, Recruiting, Sponsor: Boehringer Ingelheim
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment open: A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Dec 12, 2012
P=N/A, N=3000, Recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
New P3 trial: CAROLINA: Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug na (clinicaltrials.gov) - Oct 15, 2012
P3, N=876, Recruiting, Sponsor: Boehringer Ingelheim
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P1 trial: Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation) (clinicaltrials.gov) - Oct 8, 2012
P1, N=42, Completed, Sponsor: Boehringer Ingelheim Pharmaceuticals
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment open: Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes (clinicaltrials.gov) - Sep 4, 2012
P4, N=60, Recruiting, Sponsor: University of Padova
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Victoza (liraglutide) / Novo Nordisk, Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Byetta (exenatide) / AstraZeneca
Preclinical: The Microvascular Function of GLP-1 and Its Analogues (clinicaltrials.gov) - Aug 29, 2012
P=N/A, N=63, Recruiting, Sponsor: Katarina Kos
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Clinical: Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Jul 24, 2012
P=N/A, N=3300, Recruiting, Sponsor: Boehringer Ingelheim
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Trial completion: Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets (clinicaltrials.gov) - Jul 1, 2012
P1, N=32, Completed, Sponsor: Boehringer Ingelheim Pharmaceuticals
Not yet recruiting --> Recruiting Withdrawn --> Completed
- ||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion: Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug na (clinicaltrials.gov) - Jun 26, 2012
P3, N=300, Completed, Sponsor: Boehringer Ingelheim
Withdrawn --> Completed Active, not recruiting --> Completed
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P4 trial: Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes (clinicaltrials.gov) - Jun 10, 2012
P4, N=60, Recruiting, Sponsor: University of Padova
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Trial initiation date, Monotherapy, Head-to-Head: Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes (clinicaltrials.gov) - May 29, 2012
P4, N=316, Completed, Sponsor: Boehringer Ingelheim Pharmaceuticals
Active, not recruiting --> Completed Initiation date: Apr 2011 --> Jan 2012
- ||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion: Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment (clinicaltrials.gov) - May 29, 2012
P3, N=241, Completed, Sponsor: Boehringer Ingelheim
Initiation date: Apr 2011 --> Jan 2012 Active, not recruiting --> Completed
- ||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion: Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy (clinicaltrials.gov) - May 1, 2012
P3, N=306, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
New P1 trial: Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets (clinicaltrials.gov) - Apr 18, 2012
P1, N=32, Completed, Sponsor: Boehringer Ingelheim Pharmaceuticals
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment open: Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Apr 9, 2012
P4, N=40, Recruiting, Sponsor: Marcus Borchert
Active, not recruiting --> Completed Not yet recruiting --> Recruiting